Atrial Fibrillation Latest News Archive
Investigators observed a significant association between atrial fibrillation and increasing oxygen desaturation index.
Variations in published stroke rates for patients with AF not receiving anticoagulants result in differences in the calculated net clinical benefit of anticoagulation.
The irregular rhythm notification feature analyzes pulse rate data to identify episodes of irregular heart rhythms.
The new analysis included 19,134 of these patients and showed that there were 19% fewer deaths in patients initiated on NOACs compared to VKAs at the time of AF diagnosis.
Patients with atrial fibrillation who have ≥1 non-sex CHA2DS2VASc stroke risk factor should receive oral anticoagulation as antithrombotic therapy.
Clinical outcomes in atrial fibrillation vs atrial flutter differ in terms of ischemic stroke, heart failure hospitalizations, and all-cause mortality.
Patients with atrial fibrillation who take NSAIDs in addition to oral anticoagulants may have an increased risk for major bleeding and stroke.
Patients with higher levels of thyroid-stimulating hormone were more likely to experience atrial tachyarrhythmia after catheter ablation for atrial fibrillation.
Individuals with more frequent nighttime awakening exhibited a higher risk for atrial fibrillation.
Individuals with clinician-diagnosed asthma were at an estimated 38% higher risk for atrial fibrillation.
Apixaban demonstrated superiority over warfarin in terms of reducing the risk for major bleeding in patients with atrial fibrillation and end-stage kidney disease who were on dialysis.
Using a continuous ECG monitoring patch at home in patients at high risk for atrial fibrillation resulted in higher diagnosis rates, more anticoagulation initiation, and increased healthcare resource utilization.
Troponin-T, N-terminal pro-B-type natriuretic peptide, and growth differentiation factor-15 may offer prognostic utility on mortality and bleeding events in patients with atrial fibrillation who receive anticoagulation.
Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.
The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks.
A greater burden of atrial fibrillation or flutter in patients with paroxysmal atrial fibrillation was associated with a higher risk for stroke when not taking anticoagulants.
Patients with COPD had a nearly 2-fold increased risk for developing atrial fibrillation compared with patients without COPD.
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.
Peripheral artery disease with a borderline ankle-branchial index appears not to increase the risk for atrial fibrillation.
Anxiety may increase the risk for ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation.
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.
A meta-analysis sought to determine the effect of influenza vaccination on cardiac-related mortality in patients with heart failure.
Patients with persistent atrial fibrillation who received targeted therapy saw improvements in sinus rhythm as well as reductions in blood pressure, cholesterol, and weight.
Surgical left atrial appendage occlusion is associated with a lower risk for thromboembolism-related hospital readmission in older patients with atrial fibrillation who undergo cardiac surgery.
Patients with atrial fibrillation have a higher risk for ischemic stroke compared with patients with atrial flutter.
Cost-effective DOACs like apixaban prevent strokes better than warfarin in patients with atrial fibrillation.
Bleeding Risk, Stroke Outcomes With Edoxaban vs Enoxaparin-Warfarin for Cardioversion of Atrial Fibrillation
In patients with atrial fibrillation at high risk for stroke, edoxaban is associated with lower rates of cardiovascular death events.
Patients who had short-run atrial tachyarrhythmia experienced significantly higher rates of stroke compared with patients who did not have short-run atrial tachyarrhythmia.
Patients with atrial fibrillation who are treated with oral anticoagulants often experience renal function decline.
No significant association was found between atrial fibrillation risk and leukocyte telomere length.
FDA has cleared the KardiaBand device to recordtheir EKG to detect normal heart rhythms and atrial fibrillation.
Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement
A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.
The American College of Cardiology released an expert consensus decision pathway intended to guide clinicians in managing bleeding in patients treated with anticoagulation.
Compared with warfarin, direct oral anticoagulants lowered the risk for stroke and death risk in patients with incident atrial fibrillation.
Persistent atrial fibrillation is associated with a higher risk for mortality compared with paroxysmal atrial fibrillation.
Continuous monitoring with an insertable cardiac monitor was found to be superior at detecting subclinical atrial fibrillation compared with a Holter monitor.
The 10 mg dose of rivaroxaban substantially lowered the risk for recurrent venous thromboembolism.
A left atrial appendage closure device provided a similar level of stroke prevention to that of warfarin in patients with atrial fibrillation.
Change in inducibility status after pulmonary vein isolation is not associated with long-term freedom from recurrent arrhythmia.
Patients with atrial fibrillation had improved late survival when treated with ablation-assisted Cox-Maze IV and cardiac surgery.
Risk prediction models to assess bleeding risk in patients with atrial fibrillation may be useful for optimizing treatment.
Risk for poststroke cognitive impairment is increased by the presence of atrial fibrillation.
Classification of predominant obstructive sleep apnea in atrial fibrillation is affected by use of apneas vs hypopneas.
Patients who received synchronized left ventricular pacing with the AdaptivCRT had a lower risk of developing atrial fibrillation compared with patients who received conventional cardiac resynchronization therapy.
Daily short-term rhythm recordings may help diagnose atrial fibrillation in geriatric patients.
Women with atrial fibrillation and diabetes have higher rates for mortality and cardiovascular disease compared to men.
Patients diagnosed with new atrial fibrillation after ischemic stroke were more likely to have preexisting cardiovascular comorbidities such as hypertension, heart failure, and coronary artery disease.
Patients with atrial fibrillation who are at a low risk for stroke do not receive a major benefit from long-term aspirin therapy.
Patients treated with zoledronic acid had a higher risk for atrial fibrillation and other arrhythmias as well as heart failure vs untreated patients.
Patients with type 1 diabetes have an increased risk for atrial fibrillation.
Novel oral anticoagulants lead to a one-fifth reduction in the risk of intraocular bleeding, compared with warfarin in patients with atrial fibrillation or venous thromboembolism.
Cardiology care in patients with newly diagnosed atrial fibrillation was associated with reductions in stroke and death.
Patients with atrial fibrillation but without known coronary artery disease may not be at an increased risk for coronary events, despite elevated high-sensitivity troponin T levels.
The American Association for Thoracic Surgery recently released guidelines on the use of surgical ablation in atrial fibrillation.
The American Association for Thoracic Surgery has developed evidence-based guidelines on the use of surgical ablation for atrial fibrillation.
A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.
Children aged 15-19 years appear to have the greatest risk of developing lone atrial fibrillation.
Although stable sinus rhythm was achieved in some patients after LAA isolation, embolic stroke and LAA thrombus formation was still problematic.
The delayed start of anticoagulation treatment for atrial fibrillation has been linked to an increase risk for dementia.
Direct oral anticoagulation reduced the risk of congestive heart failure admissions and all-cause mortality in both genders.
The annual risk of sudden cardiac death/ventricular arrhythmias was higher in patients with atrial fibrillation vs patients without atrial fibrillation.
Thiazolidinediones reduced the risk of atrial fibrillation by 30% in an analysis of pooled data from 7 studies.
Renin-angiotensin system inhibition was linked with a reduced 3-year risk of all-cause mortality in patients with congestive heart failure and atrial fibrillation.
A systematic review of BMI and major adverse events in AF concluded that further evidence is necessary to clarify the relationship between obesity and AF.
Patients with atrial fibrillation taking apixaban showed significantly less intracranial hemorrhage compared with patients taking warfarin.
Inadequate therapeutic anticoagulation prior to the occurrence of ischemic stroke was found to be prevalent.
Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A
Incidence of major bleeding events was lower with dabigatran vs warfarin in atrial fibrillation ablation.
Atrial fibrillation was associated with a higher risk of adjusted in-hospital mortality and bleeding complications after both PCI and CABG.
CHADS2 scores in patients with atrial fibrillation are associated with increased risk of developing dementia.
The relationship between prestroke CHA2DS2-VASc score and stroke severity and functional outcome in patients with AF and acute ischemic stroke was evaluated.
Aggressive blood pressure treatment did not reduce atrial fibrillation recurrence after catheter ablation.
Compared with warfarin, there were lower rates of stroke with dabigatran 110 mg and 150 mg twice daily.
Patients taking apixaban were more likely to experience ischemic stroke or systemic embolism vs patients taking warfarin.
Patients with both heart failure and atrial fibrillation had a pattern of milder Alzheimer's pathology.
Low-density lipoprotein cholesterol independently predicts ischemic stroke in patients with atrial fibrillation.
Periprocedural Anticoagulation in Atrial Fibrillation: American College of Cardiology Decision Pathway
The American College of Cardiology released a decision pathway for managing periprocedural anticoagulation in patients with nonvalvular atrial fibrillation
The researchers assessed 1809 patients with incidence of stroke and atrial fibrillation.
Insulin-requiring diabetes was associated with a higher risk for stroke/systemic embolism incidence at 1-year follow-up.
The left atrial appendage closure device was found to have excellent success and low complication rates in a post-FDA approval study.
Silent cerebrovascular disease appears to increase the risk for future symptomatic stroke.
While the number of recommendations has increased, level A evidence is assigned to only 8.8% of the atrial fibrillation clinical guidelines.
About 1 in 8 patients in the ORBIT-AF II registry were given "off-label" non-vitamin K antagonist doses.
Cardiac-related death is the main cause of mortality among patients with atrial fibrillation on anticoagulants.
Pre-ablation trans-esophageal echocardiography rates dropped from 86% to 42%; meanwhile, cerebrovascular accidents occurred in only 0.40% of patients.
Reduced REM sleep was correlated with a 23% increased risk of atrial fibrillation.
All-cause death plus hospitalization possibly from bleeding were reduced in both rivaroxaban groups compared with the reference group.
Procedural data from the WATCHMAN clinical trial presented at TCT demonstrated the device implantation success rate in patients with nonvalvular atrial fibrillation.
Anticoagulation therapy may not reduce stroke risk for patients with ICDs who have only brief episodes of AT or AF.
Two studies presented at CHEST 2016 revealed that rivaroxaban lowered the risk of venous thromboembolism without increasing risk of major bleeding.
At 12 months, 56% of patients who received empirical electrical LAA isolation were recurrence-free, compared with 28% of patients who received standard ablation alone.
Patients with new-onset atrial fibrillation after CABG experience higher rates of morbidity and poor long-term survival outcomes compared to women.
Patients in the highest hs-cTnT tertile were more likely to have cerebral microbleeds and deep or infratentorial cerebral microbleeds, after adjustments.
Compared with patients taking warfarin, patients treated with rivaroxaban and dabigatran had significantly lower rates of intracranial hemorrhage, ischemic stroke or systemic, and all-cause mortality.
Cumulative alcohol consumption is associated with left atrial enlargement, which increases atrial fibrillation risk.
Patients treated with balloon ablation for atrial fibrillation had the lowest rates of cardiac tamponade.
Stroke/systemic embolism rates were comparable between patients with atrial fibrillation with or without heart failure.
Investigators identified a J-shape pattern to the prevalence of heart failure, MI, and stroke, with sharp increases just before diagnosis of atrial fibrillation.
Patients with a history of atrial fibrillation were more likely to have postprocedural bleeding, blood transfusion, heart failure, cardiogenic shock, and in-hospital mortality.
No differences between monotherapy and multiple anthrombotic therapy in rates of stroke, MACE, or death.
The Cardiology Advisor Articles
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Association Between Statins and Depression Likely Mediated by Confounding
- Occupational Metal, Pesticide Exposure May Be Associated With Increased CVD Risk
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Trends in Endocarditis Incidence After Implementation of 2007 AHA Recommendations
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals